XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. Related: Red Meat Allergy Test Gets FDA Clearance.

Allergies 98

Allergies Antibody In-Vitro Development 98

Scienmag

OCTOBER 9, 2020

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralized SARS-CoV-2 infection in cultured cells, according to a new study.

In-Vitro 40

In-Vitro Antibody Allergies Medicine 40

Scienmag

DECEMBER 11, 2020

10, 2020) — An in vitro study published in theJournal of Dietary Supplements, demonstrated Blue California’s ErgoActive® ergothioneine helped to preserve telomere length and reduced the rate of telomere shortening under oxidative stress. The in vitro study is […].

In-Vitro 53

In-Vitro Allergies Medicine 53

Scienmag

MARCH 30, 2021

In vitro treatment of cells with these molecules reduced the expression of a gene that plays a key role in viral cell entry and a cytokine receptor.

In-Vitro 55

In-Vitro Gene Allergies Medicine 55

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Previously, he held roles as CMO at Trimeris Inc.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

OCTOBER 22, 2020

Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States. The drug is now widely available in hospitals across the country, following early investments to rapidly expand manufacturing capacity to increase supply.

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 6, 2021

(“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. Cyto-111 was conceived, expressed and purified in the laboratory of Konstantin Ichtchenko, Ph.D.,

Medicine 52

Medicine Antibody Protein In-Vitro 52